Background. The intratracheal administration of a perfluorocarbon liquid during continuous positivepressure ventilation (partial liquid ventilation) improves lung function in animals with
Surfactant replacement therapy, improvements in ventil-
Extracorporeal membrane oxygenation (ECMO) ECMO employs a membrane oxygenator to effect gas atory strategies, and the widespread use of antenatal steroids have had an enormous impact on neonatal exchange in an extracorporeal circulation and has been used successfully as an adjunct to ventilatory respiratory disease. The majority of babies with respiratory failure are now expected to respond to consupport in infants with reversible respiratory failure. The initial enthusiasm for ECMO led to its widespread ventional time cycled, pressure limited ventilation with surfactant replacement therapy, and to survive.
use, particularly in North America, without any convincing evidence from large randomised controlled However, as survival is not always assured, several alternative treatment modalities aimed at treating restrials of its benefit over conventional treatments. However, a large multicentre randomised controlled trial piratory failure in sick babies, either as a primary treatment or rescue therapy, have been developed over recent of the use of ECMO for severe respiratory failure in term and near term neonates has recently been years. The introductory article by Leach and colleagues describes the newest of these treatments -partial liquid performed in the UK 1 in which the mortality in the group treated with conventional therapy was apventilation (PLV) with perfluorocarbons. It is worthwhile briefly considering the current status of some of proximately 60% and ECMO halved the chance of death (RR with ECMO=0.55 (95% CI 0.39 to 0.77) ). the other treatments in order to identify the possible role for PLV in the newborn and to understand the The success of ECMO in this study was different with different diagnoses. A much better improvement in importance of critical evaluation of new technologies in neonatal intensive care.
survival was seen in babies with meconium aspiration syndrome than in those with congenital diaphragmatic the need for home oxygen therapy in a multiple logistic regression analysis. hernia.
ECMO can only be applied to larger infants because Only one of the five studies found a reduction in the incidence of air leaks in babies receiving HFOV 2 and of technical considerations, not least the difficulty in establishing adequate vascular access in smaller babies.
this was mostly due to a reduction in mild pulmonary interstitial emphysema. There were significant concerns It is not used routinely in preterm infants below 34 weeks gestation because of concern that the associated raised by two studies in which an increased incidence of intracranial haemorrhage occurred in babies receiving haemodynamic disturbance and the need for anticoagulation may increase the risk of major intracranial HFOV, 2 6 although this was not confirmed by the other three studies. haemorrhage.
The success of ECMO in managing severe respiratory The use of HFOV as a rescue therapy for preterm babies not responding to conventional management has failure in term and near term babies has thus been very impressive and any new treatments for such babies not been evaluated by a randomised controlled trial and there is no convincing evidence of its benefit in more would need to be evaluated by comparison with ECMO. However, ECMO is not available for the treatment of mature babies. The use of HFOV as the primary mode of ventilatory support in preterm babies with respiratory small preterm babies with severe respiratory failure and other treatment modalities need to be evaluated.
failure has been shown to have no effect on mortality and it has not been convincingly shown to reduce the incidence of clinically significant BPD.
High frequency oscillatory ventilation (HFOV)
This mode of ventilation relies on maximal recruitment
Inhaled nitric oxide (NO)
Nitric oxide is an endogenous vasodilator which is of respiratory units to improve oxygenation by the use of a high mean airway pressure. The generation of produced by vascular endothelium and induces relaxation of underlying smooth muscle cells. Inhaled NO rapid small tidal volumes using oscillation with active inspiration and active expiration improves elimination is rapidly inactivated by binding to haemoglobin and therefore has vasodilator effects specific to the pulof CO 2 . It has been suggested that the small changes in lung volume which occur during HFOV may decrease monary circulation (unlike other pulmonary vasodilators). Pulmonary hypertension is a common feature the risk of air leaks and bronchopulmonary dysplasia (BPD). This treatment is widely used as a rescue therapy in infants with respiratory failure. Inhaled NO may improve oxygenation in these infants through either a in babies who do not respond to conventional ventilation. It has also been adopted by some neonatologists reversal of extrapulmonary shunting or a redistribution of pulmonary blood flow and enhanced ventilationas the primary mode of respiratory support for babies with respiratory failure. perfusion matching. It has recently been shown that NO can reduce the Several randomised controlled trials in neonates have shown short term improvements in gas exchange with need for ECMO in term neonates with severe respiratory failure. 8 In a randomised controlled trial in preterm HFOV compared with conventional mechanical ventilation.
2-4 However, the long term benefits from this neonates at high risk for developing BPD, NO has been shown to cause a short term reduction in the oxygenation mode of ventilation have unfortunately been less impressive to date.
index and the pulmonary artery pressure. 9 However, our own (unpublished) observations in this population There are no published randomised controlled trials of the use of HFOV as a rescue therapy in preterm have shown that these effects were not sustained and did not reduce mortality or the incidence of BPD. neonates. The only published trial in term and near term infants found that the proportion of babies who
Further multicentre clinical trials of the use of NO in sick neonates are in progress. responded to HFOV was not significantly different from those treated with continued conventional ventilation.
5
This study also failed to demonstrate a significant difference in mortality or the need for ECMO.
Liquid ventilation
There are three theoretical advantages to ventilating the There are five published randomised controlled trials, involving some 822 subjects, comparing the use of lung with liquid rather than gas. Firstly, removal of the air/fluid interface within the alveolus results in a HFOV against conventional ventilation as a primary means of respiratory support in preterm babies.
2-4 6 7 reduction of surface tension and an associated increase in compliance;
10 secondly, lung volume may be recruited None of these trials has found an improvement in survival with HFOV use.
by inflation of atelectatic alveoli; 11 and thirdly, the continuous alveolar lavage provided by liquid ventilation The effect of HFOV on development of BPD or air leaks is less clear. Two studies found no difference in may be of benefit by reducing the alveolar load of inflammatory mediators. the rate of BPD, 3 6 and a third did not report the incidence of BPD but found no difference in the need Several groups have explored liquid ventilation in animal models using different liquids. 12 Although saline for ventilatory support at 30 days.
2 A further study 7 demonstrated a decrease in the incidence of BPD (dewas the first liquid to be studied, the poor solubility of respiratory gases in saline made it unsatisfactory for use. fined as oxygen dependency and an abnormal chest radiograph at 36 weeks post-conceptional age) with Successful liquid ventilation has been achieved using oxygenated oils. None of the oils used were suitable for HFOV, but no reduction in the need for supplemental oxygen at hospital discharge or in age at hospital dislong term ventilation because of their direct toxic effects on the lungs. charge. The fifth study by Gerstmann et al 4 also found less BPD (defined as a lower "chronic lung disease
The perfluorocarbons (PFCs) are biologically inert, clear, colourless liquids which have a higher density score" at 30 days) in those babies treated with HFOV, and fewer of the babies receiving HFOV required supthan the tissues and are immiscible with body fluids. They are able to dissolve large amounts of respiratory plemental oxygen at hospital discharge, although the mode of ventilation used did not predict independently gases. These physical properties make them a potentially daily dosing of perflubron for up to seven days in neonatal, paediatric, and adult patients, all of whom Theoretical advantages of liquid ventilation were also concurrently receiving ECMO for their severe with perfluorocarbons
• Reduction of surface tension with improvement in respiratory failure. [28] [29] [30] [31] [32] They reported an increase in pulmonary compliance pulmonary compliance in all groups over a three to four
• Recruitment of atelectatic alveoli day period of treatment and an increase in indices of
• Continuous alveolar lavage oxygenation in all groups over the same time. Short
• High respiratory gas solubility term improvements in these parameters were also found
• Biologically inert in the group of babies with congenital diaphragmatic hernia shortly after each dose of perflubron. All of these patients were also receiving numerous other therapeutic interventions. The lack of control data from these studies makes it impossible to determine to what extent PLV suitable medium for use in liquid ventilation (see box). Perflubron -the PFC used in the paper by Leach et al 13 was responsible for any of the observed improvements in the physiological parameters. Five of the 10 adults, -is an eight carbon chain in which all of the available binding sites are occupied by fluoride apart from one all six of the children, and two of the four neonates survived their illness. The lack of control data also makes terminal position which is occupied by bromide, making the compound radio-opaque.
it impossible to determine whether PLV contributed to an improvement in survival. The patients in these studies The first reported experience with liquid ventilation using perfluorocarbons was by Clark and Gollan in had numerous other clinical problems, but these were felt to be in keeping with their underlying severe illness 1966 14 who described the method in spontaneously breathing mice. Two methods of mechanical ventilation rather than a consequence of the PLV. Again, lack of control data make it impossible to assess properly the with PFCs have subsequently been developed. Total liquid ventilation (TLV) requires filling of the lungs role of PLV in the development of these problems. Small pleural leaks of perflubron occurred in a few patients with PFC and the generation of a tidal volume of PFC using a specifically designed liquid ventilator. The who had developed pneumothorax, but these appeared to cause no major clinical problems and resolved sponphysical properties of PFCs -notably, the higher density and viscosity and the slower gas diffusion rates -mean taneously. The paper by Leach et al 13 is a description of the use that effective gas exchange can only be performed in TLV using slow rate ventilation. 10 In partial liquid ventof PLV in a group of 13 neonates with severe respiratory failure. Eight of the 10 babies treated using the study ilation (PLV), or perfluorocarbon associated gas exchange (PAGE), the lung is filled with PFC to a protocol survived. These babies were too small to have undergone ECMO. There are no other reports of liquid functional residual capacity and a tidal volume of gas is generated using conventional gas ventilation. Both ventilation in humans in peer reviewed journals, although some data are beginning to appear in abstract techniques have been shown to improve gas exchange in animal models of lung injury and respiratory form 33 and clinical trials are currently underway in North America. failure.
15 16 A recent study 17 has suggested that lung compliance is greater during TLV than PLV, although this may have been due to the method used to assess compliance.
Practical aspects of use
In the study by Leach et al infants received PLV with Liquid ventilation has been used in various animal models of acute lung injury and ARDS. [15] [16] [17] [18] [19] It has also perflubron and conventional time cycled, pressure limited ventilation. The mean amount of perflubron inbeen used in neonatal animals with hyaline membrane disease, 20-22 congenital diaphragmatic hernia, 23 24 and stilled was 15 ml/kg over a mean period of 25 minutes. Additional perflubron was given to replace evaporative meconium aspiration syndrome. 25 These studies have shown that the technique can be used to achieve suclosses to maintain a meniscus in the endotracheal tube. While perflubron was being instilled, ventilator settings cessful ventilation in these situations.
Liquid ventilation decreases the severity of exwere altered to maintain reasonably constant tidal volume. If liquid ventilation became more widespread, perimental lung injury. 17 It is likely that this is due to a reduction in barotrauma or in the intra-alveolar conthe rate of instillation and replacement of perflubron together with the amount used may have to be more centration of inflammatory mediators by continuous alveolar lavage. However, it has been suggested that critically evaluated. An attempt was made to return to gas ventilation PFCs may have a direct effect on the inflammatory process. 26 Clearly, if PFCs are shown to exert a direct after 48 hours of beginning perflubron instillation based on the premise that it takes approximately this length anti-inflammatory effect, they cannot be considered as biologically inert and studies of the long term biological of time for the lung to mature in response to other interventions such as antenatal corticosteroids and sureffects will be necessary.
Liquid ventilation in humans was first described in factant. This may only apply in the immediate newborn period. In the study infants were treated any time up 1990 by Greenspan et al 27 who reported its use in three moribund neonates. Each of the subjects had two short to five days of age. At this stage an acute inflammatory response in the lung is likely to have occurred and the cycles of TLV (3-5 minutes) separated by 15 minutes of conventional gas ventilation. Two of the three babies response of the lung to any intervention is likely to be different from the response in the immediate newborn had an increase in Pa 2 after liquid ventilation and all showed an increase in lung compliance. In a later report period. Thus, the optimal length of time to use perflubron may be different (longer or even shorter). by the same group 12 a further three babies were studied and similar findings were reported. All six babies subThe decision to resume liquid ventilation for a maximal cumulative treatment of 96 hours was made if the sequently died as predicted prior to their recruitment.
The group in Ann Arbor, Michigan have published oxygenation index increased to a value that was 30% higher than the value when PLV was stopped. The a series of papers documenting their experience of the use of PLV in humans. This work describes PLV with threshold for resuming liquid ventilation is likely to have group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from ministered exogenous surfactant, or even a newly formed 
term?
Oxygenation index (OI)
The paper describes a number of short term outcome tensions (Pa 2 and Pa 2 ), dynamic compliance, ventilatory requirements, and oxygenation index. One concern of the authors of this paper is that three infants who had refractory hypercapnia and received high frequency ventilation were withdrawn from PLV been an empirical one. In order to calculate sample size because of recurrent hypercapnia. These infants do not appropriately and accurately, the evaluation of the need appear to have been included in the analysis of short to resume liquid ventilation in any randomised trial of term outcome measures although it is arguable that its efficacy might be better studied as a separate issue these three infants were the most severely ill of the once the outcome is determined for a short course of group. Despite this, two of them survived, which casts liquid ventilation.
some doubt on the severity of risk of infants entered into the study. Fractional inspired oxygen concentration, Pa 2 , Is it safe? mean airway pressure, and oxygenation index all deThe prime aim of the study by Leach et al was to assess creased in association with PLV and dynamic comthe safety of PLV. This was assessed on the basis of pliance of the lung increased. On the face of it, therefore, heart rate, blood pressure, chest radiographs, cranial PLV is associated with an improvement in short term ultrasonographic studies, and clinical laboratory values outcome in selected infants. However, the baseline range obtained during liquid ventilation. The authors admit of many of the parameters of short term outcome that that the ability to identify complications of PLV was were measured was wide. Improvements associated with limited by the uncontrolled design of their study and PLV should be accepted with caution until similar outthe small number of infants. A number of complications comes in a control group have been compared. ascribed to prematurity occurred -specifically, intracranial haemorrhage, pneumothorax, and upper gastrointestinal haemorrhage. That liquid ventilation did not contribute to any of these and, indeed, was not a
Might it have a benefit in the long term?
The main question with any new experimental treatment contributing cause in those infants who died cannot be completely ruled out. It was suggested that endotracheal must be whether the incidence of significant long term outcome measures is altered by the use of such a tube obstruction and transient hypoxaemic episodes might have been related to the PLV. The material treatment. Death, chronic lung disease, and neurodevelopmental outcome are arguably the main long obtained from the blocked endotracheal tubes was mucoid in nature and viscous and tenacious. It appeared term outcome measures which are important in neonatal medicine. in greater amounts than during gas ventilation and could be removed by suctioning with saline. The authors Some early clinical trials of other therapies in newborn infants with severe respiratory failure have selected inspeculated that this material may have been a preexisting exudate, endogenous surfactant, previously adfants with a poor prognosis for "rescue" treatment. 53 
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Exosurf
Decrease in OI by <25% within 6 hours of 50% 22% surfactant Kuint 48 
Curosurf
Increase in a/A by <0.112 one hour after 50% 45% surfactant a/A=ratio of arterial to alveolar oxygen tension; MAP=maximum arterial pressure; FiO 2 =fractional inspired oxygen. Prognosis was assessed using data from retrospective lights how vital it is to calculate risk with conventional treatment in one's own population, at least when comstudies. Parameters of oxygenation and/or respiratory support were used to identify a "high risk" group in paring the results of a pilot study of an experimental treatment using historical controls. whom the mortality was expected to exceed 80-90%. [37] [38] [39] [40] [41] [42] [43] Although various such attempts to quantify disease
The data presented in the paper by Leach et al do not suggest that PLV leads to improved survival in severe severity in term and preterm infants have been made (tables 1 and 2), there is still little consensus regarding respiratory distress syndrome although, as previously discussed, the technique appears feasible and possibly the criteria which are the most reliable predictors of eventual outcome. Few methods of assessing disease safe in the short term. There are unanswered questions as to its long term safety and only a larger randomised severity have been validated prospectively. 44 45 Nevertheless, clinical studies using such criteria to predict trial can yield information on its long term efficacy. mortality have often reported improved survival in treated infants and, generally, the authors have con- applied to a different population at a different time. 
